BTK gene therapy (CSL Behring/Seattle Children's Research Institute)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameBTK gene therapy (CSL Behring/Seattle Children's Research Institute)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsAgammaglobulinemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSeattle Children'S Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeattle Children'S Research InstituteCsl Behring Llc
Active IndicationsN/A
Inactive IndicationsAgammaglobulinemia

Other Information

ATC CodeN/A
Related LinksN/A